1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Empire State Realty Trust and its operating partnership entered a First Amendment to their credit agreement with Wells Fargo as administrative agent, creating term loan and delayed draw term loan facilities of up to $490 million in initial principal, with a possible increase to $510 million. The term loan of $245 million was already fully borrowed before the closing date, and the delayed draw of $245 million may be drawn over the six months after July 17, 2026, with the facility funding working capital, capital expenditures, acquisitions, and development.
Facility totals up to $490 million: a $245 million term loan (fully borrowed before July 17, 2026) and a $245 million delayed draw term loan
Maximum aggregate principal may be increased to $510 million
Floating rates are SOFR plus 1.50% to 2.05%, or base rate plus 0.50% to 1.05%, depending on leverage ratio; delayed draw unused fee is 0.20%
Term loan matures January 15, 2029 (extendable to January 15, 2031); delayed draw matures January 12, 2032
Penguin Solutions issued $750.0 million of 0.00% convertible senior notes due August 1, 2031, including a $100.0 million option that the initial purchasers exercised in full. The company is using the estimated $735.1 million in net proceeds to repurchase $295.5 million of existing 2029 and 2030 convertible notes, pay $49.1 million for capped call transactions, and repay $100.0 million under a credit agreement. The new notes are convertible at an initial price of about $116.70 per share, and the capped calls are intended to reduce potential dilution.
$750.0 million principal, 0.00% interest rate, maturing August 1, 2031; initial conversion price of about $116.70 per share
Estimated net proceeds of $735.1 million, including about $136.7 million to repurchase $135.5 million of 2029 notes and about $161.4 million to repurchase $160.0 million of 2030 notes
Capped call cost of about $49.1 million with an initial cap price of $175.05 per share; $100.0 million used to repay the credit agreement
Advanced Biomed Inc. gave notice on July 14, 2026 to terminate its June 6, 2025 purchase agreement with Helena Global Investment Opportunities I Ltd., which allowed the company to sell up to $25,000,000 of common stock to the investor at its discretion. The filing states no shares were sold under the agreement apart from commitment fee shares, and the termination takes effect July 21, 2026, so the company will no longer have this equity financing option.
Purchase agreement dated June 6, 2025 allowed sales of up to $25,000,000 of common stock to Helena Global Investment Opportunities I Ltd.
Termination notice delivered July 14, 2026 under Section 11.02(b), which requires five trading days' notice.
No advances were outstanding and all amounts owed, including commitment fee shares, were paid, per the filing.
NanoViricides, Inc. entered into an at-the-market sales agreement with D. Boral Capital LLC, allowing it to sell common stock from time to time under an existing shelf registration. The filing does not state a dollar amount or number of shares, and sales are not required to occur; the company pays a 2.0% commission on gross proceeds from any sales, which would add shares outstanding and dilute existing holders.
Agreement dated July 17, 2026, with D. Boral Capital LLC as sales agent
Commission of 2.0% of aggregate gross proceeds from each sale
Shares sold under Form S-3 (File No. 333-296550), declared effective June 15, 2026
Sales may be made on the NYSE American or in privately negotiated transactions with company consent
Avantor Funding, a wholly owned subsidiary of Avantor, entered into Amendment No. 15 to its credit agreement on July 14, 2026, to obtain a €374,208,296.62 tranche of senior secured euro term loans. The new loans replace and refinance part of existing euro term loans that carried a higher spread, lowering the stated spread from 2.50% to 2.00% and maturing on October 9, 2032. The filing does not state a change to total debt, and a 1.00% prepayment premium applies if the loans are repriced within six months.
Incremental B-7 Euro Term Loans of €374,208,296.62 bear interest at EURIBOR plus 2.00%, down from 2.50% on the loans they replaced
Final maturity is October 9, 2032, the same date as the refinanced loans
A 1.00% prepayment premium applies to certain repricing transactions completed before the six-month anniversary of July 14, 2026
Loans are guaranteed and secured on a pari passu basis with the existing credit facilities
Hilton Grand Vacations entered into Amendment No. 10 to its credit agreement, under which the Borrower incurred an $850.0 million new term loan maturing July 17, 2033. Proceeds will repay in full about $849.0 million of an existing term loan due 2028, with the remainder for general corporate purposes. The filing does not include financial results, but it refinances existing debt and extends the maturity of that borrowing to 2033.
New $850.0 million term loan; about $849.0 million of the existing term loan due 2028 will be repaid in full.
Matures July 17, 2033, with quarterly repayments of 0.25% of original principal starting with the quarter ending December 31, 2026.
Interest at Term SOFR plus 2.00% or base rate plus 1.00%, with a 0% Term SOFR floor.
Guaranteed by Holdings and subsidiary guarantors and secured by a first-priority interest in substantially all of their assets.
Tvardi Therapeutics filed a prospectus supplement on July 17, 2026, raising its at-the-market share sale capacity under its JonesTrading sales agreement by up to $9,689,765. The filing says the company is subject to the SEC's baby shelf rule, which caps sales based on non-affiliate market value, and that no further shares will be sold under the prior prospectus after the supplement date. For shareholders, the expansion signals potential dilution from additional share issuance.
On July 17, 2026, the company filed a prospectus supplement allowing issuance of up to $9,689,765 in shares, in addition to amounts previously sold.
Baby shelf limits apply: non-affiliate market value is $62,208,945, based on 12,441,789 shares at $5.00 on July 8, 2026.
In the prior twelve months, the company sold 3,110,769 shares for about $11.0 million in gross proceeds under the sales agreement.
The Sales Agreement with JonesTrading Institutional Services LLC was entered into on May 1, 2026; Cooley LLP's legal opinion is filed as Exhibit 5.1.
Csquare sold 50,000,000 shares of common stock at $21.00 per share in its initial public offering, with the sale closing on July 17, 2026 and providing net proceeds of $1,010.0 million. The company also entered agreements with Brookfield that give Brookfield board nomination rights and registration rights for its shares, and it amended its charter and bylaws in connection with the offering.
50,000,000 shares sold at $21.00 per share; underwriters have a 30-day option to buy up to 7,500,000 additional shares
Net proceeds to the company of $1,010.0 million after underwriter discounts and commissions; sale closed July 17, 2026
Stockholders Agreement with Brookfield lets it nominate directors while it owns at least 5% of outstanding common stock
Amended and restated certificate of incorporation and bylaws adopted July 15, 2026
On July 15, 2026, Uniti Group subsidiary Kinetic ABS Issuer LLC completed a private offering of $1,140,710,000 in secured fiber network revenue term notes, the second issuance in its fiber-to-the-home securitization program. The company says it intends to use the net proceeds for general corporate purposes, which may include success-based capital expenditures and/or repaying debt.
Class A-2 notes $805,210,000 at 5.834%, Class B $134,200,000 at 6.224%, Class C $201,300,000 at 7.536%
Notes issued at 100% of principal, with an anticipated repayment date in June 2033 and a legal final maturity in June 2058
Interest is payable monthly on the 25th, starting August 25, 2026
About $91,081,390 is held in a prefunding account for Oklahoma assets pending regulatory approvals; if those sales do not close by July 30, 2027, the funds prepay the notes
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.